Des bactéries pour prévenir et traiter le cancer du col de l’utérus induit par le papillomavirus humain de type 16

Luis Bermudez-Humaran; Philippe Langella

doi:10.1051/medsci/2006225472

Accueil

Tous les numéros

Volume 22 / Numéro 5 (Mai 2006)

Med Sci (Paris), 22 5 (2006) 472-473

Références

Accès gratuit

Numéro		Med Sci (Paris) Volume 22, Numéro 5, Mai 2006


Page(s)		472 - 473
Section		Nouvelles
DOI		https://doi.org/10.1051/medsci/2006225472
Publié en ligne		15 mai 2006

Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000: the global picture. Eur J Cancer 2001; 37 (suppl 8) : S4–66. [Google Scholar]
Koutsky LA, Ault KA, Wheeler CM, et al. Proof of principle study investigators. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002; 347 : 1645–51. [Google Scholar]
Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women : a randomised controlled trial. Lancet 2004; 364 : 1757–65. [Google Scholar]
Hanniffy S, Wiedermann U, Repa A, et al. Potential and opportunities for use of recombinant lactic acid bacteria in human health. Adv Appl Microbiol 2004; 56 : 1–64. [Google Scholar]
Cortes-Perez NG, Bermúdez-Humarán LG, Le Loir Y, et al. Mice immunization with recombinant Lactococcus lactis displaying a cell-wall anchored human papillomavirus type 16 E7 protein. FEMS Microbiol Lett 2003; 229 : 37–42. [Google Scholar]
Bermúdez-Humarán LG, Cortes-Perez NG, Alcocer-González JM, et al. An inducible surface presentation system improves cellular immunity against E7 antigen after nasal administration with recombinant lactococci. J Med Microbiol 2004; 53 : 1–7. [Google Scholar]
Bermúdez-Humarán LG, Langella P, Cortes-Perez NG, et al. Intranasal immunization with recombinant Lactococcus lactis secreting murine interleukin-12 enhances antigen-specific Th1 cytokine production. Infect Immun 2003; 71 : 1887–96. [Google Scholar]
Lin KY, Guarnieri FG, Staveley-O’Carroll KF, et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 1996; 56 : 21–6. [Google Scholar]
Bermúdez-Humarán LG, Cortes-Perez NG, Lefèvre F, et al. A novel mucosal vaccine based on live lactococci expressing E7 antigen and IL-12 induces systemic and mucosal immune responses and protects mice against human papillomavirus type 16-induced tumors. J Immunol 2005; 175 : 7297–302. [Google Scholar]
Liu XS, Abdul-Jabbar I, Qi YM, et al. Mucosal immunisation with papillomavirus virus-like particles elicits systemic and mucosal immunity in mice. Virology 1998; 252 : 39-45.EDK 25/2/06 [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.

[1] Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000: the global picture. Eur J Cancer 2001; 37 (suppl 8) : S4–66. [Google Scholar]

[2] Koutsky LA, Ault KA, Wheeler CM, et al. Proof of principle study investigators. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002; 347 : 1645–51. [Google Scholar]

[3] Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women : a randomised controlled trial. Lancet 2004; 364 : 1757–65. [Google Scholar]

[4] Hanniffy S, Wiedermann U, Repa A, et al. Potential and opportunities for use of recombinant lactic acid bacteria in human health. Adv Appl Microbiol 2004; 56 : 1–64. [Google Scholar]

[5] Cortes-Perez NG, Bermúdez-Humarán LG, Le Loir Y, et al. Mice immunization with recombinant Lactococcus lactis displaying a cell-wall anchored human papillomavirus type 16 E7 protein. FEMS Microbiol Lett 2003; 229 : 37–42. [Google Scholar]

[6] Bermúdez-Humarán LG, Cortes-Perez NG, Alcocer-González JM, et al. An inducible surface presentation system improves cellular immunity against E7 antigen after nasal administration with recombinant lactococci. J Med Microbiol 2004; 53 : 1–7. [Google Scholar]

[7] Bermúdez-Humarán LG, Langella P, Cortes-Perez NG, et al. Intranasal immunization with recombinant Lactococcus lactis secreting murine interleukin-12 enhances antigen-specific Th1 cytokine production. Infect Immun 2003; 71 : 1887–96. [Google Scholar]

[8] Lin KY, Guarnieri FG, Staveley-O’Carroll KF, et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 1996; 56 : 21–6. [Google Scholar]

[9] Bermúdez-Humarán LG, Cortes-Perez NG, Lefèvre F, et al. A novel mucosal vaccine based on live lactococci expressing E7 antigen and IL-12 induces systemic and mucosal immune responses and protects mice against human papillomavirus type 16-induced tumors. J Immunol 2005; 175 : 7297–302. [Google Scholar]

[10] Liu XS, Abdul-Jabbar I, Qi YM, et al. Mucosal immunisation with papillomavirus virus-like particles elicits systemic and mucosal immunity in mice. Virology 1998; 252 : 39-45.EDK 25/2/06 [Google Scholar]